Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in BioMarin Pharmaceutical Inc., Halozyme Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Latest Biotechnology and BioMarin Pharmaceutical Inc., Halozyme Therapeutics, Inc. Stock News

As of December 2, 2025, BioMarin Pharmaceutical Inc. had a $10.4 billion market capitalization, compared to the Biotechnology median of $200.6 million. BioMarin Pharmaceutical Inc.’s stock is down 18.4% in 2025, down 4.7% in the previous five trading days and down 15.18% in the past year.

Currently, BioMarin Pharmaceutical Inc.’s price-earnings ratio is 20.5. BioMarin Pharmaceutical Inc.’s trailing 12-month revenue is $3.1 billion with a 16.8% net profit margin. Year-over-year quarterly sales growth most recently was 4.1%. Analysts expect adjusted earnings to reach $3.577 per share for the current fiscal year. BioMarin Pharmaceutical Inc. does not currently pay a dividend.

As of December 2, 2025, Halozyme Therapeutics, Inc. had a $7.8 billion market cap, putting it in the 76th percentile of all stocks. Halozyme Therapeutics, Inc.’s stock is up 39.5% in 2025, down 8.4% in the previous five trading days and up 42.5% in the past year.

Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 14.4. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.2 billion with a 47.9% net profit margin. Year-over-year quarterly sales growth most recently was 22.1%. Analysts expect adjusted earnings to reach $6.138 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.

How We Compare BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
BioMarin Pharmaceutical Inc.	BMRN	A
Halozyme Therapeutics, Inc.	HALO	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

BioMarin Pharmaceutical Inc. has a Growth Score of 87, which is Very Strong. Halozyme Therapeutics, Inc. has a Growth Score of 70, which is Strong.

The Growth Grade Winner: BioMarin Pharmaceutical Inc.

As you can clearly see from the Growth Grade breakdown above, BioMarin Pharmaceutical Inc. has a more attractive growth grade than Halozyme Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, BioMarin Pharmaceutical Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
BioMarin Pharmaceutical Inc.	BMRN	A
Halozyme Therapeutics, Inc.	HALO	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

BioMarin Pharmaceutical Inc. has a Quality Score of 90, which is Very Strong. Halozyme Therapeutics, Inc. has a Quality Score of 98, which is Very Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. have a grade of A. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
BioMarin Pharmaceutical Inc.	BMRN	D
Halozyme Therapeutics, Inc.	HALO	B

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

BioMarin Pharmaceutical Inc. has a Momentum Score of 33, which is Weak. Halozyme Therapeutics, Inc. has a Momentum Score of 69, which is Strong.

The Momentum Grade Winner: Halozyme Therapeutics, Inc.

As you can clearly see from the Momentum Grade breakdown above, Halozyme Therapeutics, Inc. is considered to have stronger momentum compared to BioMarin Pharmaceutical Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Halozyme Therapeutics, Inc. could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. Grades

In addition to Momentum, Growth and Quality, A+ Investor also provides grades for Value and Estimate Revisions.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, BioMarin Pharmaceutical Inc., Halozyme Therapeutics or Inc. Stock?

Overall, BioMarin Pharmaceutical Inc. stock has a Growth Score of 87, Momentum Score of 33 and Quality Score of 90.

Halozyme Therapeutics, Inc. stock has a Growth Score of 70, Momentum Score of 69 and Quality Score of 98.

Comparing BioMarin Pharmaceutical Inc., Halozyme Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.